drugset / Trial / NCT02346318

The Randomized Controlled Clinical Trial of Kushen Injection

NCT02346318 ↗

Phase 4 Unknown 240 enrolled Beijing Zheng Ju Medical Technology Co., Ltd.
RandomizedParallel-groupOpen-labelPrevention

Summary

The randomized controlled multicenter clinical study of compound Kushen Injection to reduce the radiotherapy related adverse reactions in lung cancer is a phase Ⅳ clinical trials,The main purpose is to evaluate the effect of compound Kushen Injection in preventing and reducing the radiotherapy related adverse reactions. The participants of the clinical trials are patients with lung cancer who need thoracic radiotherapy. In clinical trials, one group of participants is given compound Kushen Injection with chemoradiotherapy, while another group is only given chemoradiotherapy. The period of trials is 18 months.

Timeline

Start
2014-11
Primary completion
2017-08
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Compound Kushen Injection Unknown 20 ml Intravenous

Indications